METABOLIC & WEIGHT RESEARCH / MATRIX
One Fragment, One Amplifier, One Dual Agonist
How AOD-9604, tesamorelin, and tirzepatide differ in mechanism, evidence strength, regulatory status, and the one caution that matters most for each.
The short version
This page lines up AOD-9604, tesamorelin, and tirzepatide on the dimensions that actually matter when comparing peptides grouped loosely under 'weight management': what receptor or pathway each engages, what population each was actually tested in, how strong that evidence is, and what regulatory status each currently holds. The honest summary is that these three are not interchangeable alternatives to the same problem — they sit at three different points on a spectrum from a failed human trial, to a narrow approval, to a broad approval with a large measured effect. None of what follows is medical advice, and no dose is recommended for any compound.
The comparison matrix
| Dimension | AOD-9604 | Tesamorelin | Tirzepatide |
|---|---|---|---|
| Class | Synthetic hGH C-terminal fragment (16 aa) | Synthetic GHRH(1-44) analogue (44 aa) | Dual GIP/GLP-1 receptor agonist (39 aa) |
| Primary mechanism | Antilipogenic / lipolytic via ACC inhibition and beta-3 adrenergic receptor up-regulation [4] | Stimulates pituitary GH release via the GHRH receptor [9] | Activates GIP and GLP-1 receptors; enhances insulin secretion, suppresses glucagon, slows gastric emptying [16] |
| Most-studied in | Human obesity; osteoarthritis (rabbit, preclinical) | HIV-associated lipodystrophy (visceral / liver fat) | Type 2 diabetes, obesity, sleep apnea |
| Evidence base | ~900-subject human trial program; did not beat placebo on weight [3] | Multiple RCTs, including a 2026 five-trial meta-analysis [6] | Large phase 3 programs (SURMOUNT, SURPASS) plus a head-to-head trial [11][14][15] |
| Regulatory status | Never approved; obesity program discontinued | FDA-approved (2010) for HIV-associated lipodystrophy only | FDA-approved for type 2 diabetes, weight management, and sleep apnea |
| Key caution | Human efficacy unproven; investigational-only material [3] | Effect not permanent; reaccumulates fat after stopping [10] | GI intolerance and gallbladder / biliary-disease signal [13] |
Mechanism
The three take fundamentally different routes to the same broad goal. AOD-9604 tries to isolate one specific action of growth hormone — its fat-metabolizing effect — into a smaller molecule that avoids GH's growth-promoting and glucose-raising properties, working through acetyl-CoA carboxylase inhibition and beta-3 adrenergic receptor signaling in fat tissue [4][5]. Tesamorelin works a level upstream of that: rather than delivering a GH-derived molecule at all, it stimulates the pituitary gland to produce more of the body's own growth hormone in its natural pulsatile pattern, which then raises IGF-1 and drives fat breakdown mainly in visceral fat [9]. Tirzepatide abandons the growth-hormone axis entirely and instead engages two separate gut-hormone receptor systems — GIP and GLP-1 — that govern insulin secretion, glucagon suppression, gastric emptying, and appetite [16][17]. Only tirzepatide directly targets appetite and food intake at the receptor level; the other two work through fat-tissue and hormonal-axis effects.
Evidence base
This is where the three separate most sharply. Tirzepatide's evidence comes from multiple large, randomized phase 3 trials spanning thousands of participants across several indications, including a direct head-to-head comparison against semaglutide [11][14][15]. Tesamorelin's evidence is smaller in scale but consistent and repeated: multiple randomized trials in a defined population, synthesized in a 2026 meta-analysis that confirmed the visceral-fat, liver-fat, and lean-mass effects first shown in earlier work [6][8][10]. AOD-9604's evidence base is, in a sense, the most complete story of the three, precisely because it includes a negative result: roughly 900 human subjects were studied, safety was reassuring, and the drug still did not clear its efficacy bar [3]. A well-run trial that fails is still real evidence — it is simply evidence against, not for.
Regulatory and approval status
Tesamorelin and tirzepatide are FDA-approved prescription medicines, but for different reasons and different populations. Tesamorelin's approval covers a single, specific use: reducing excess visceral fat in HIV-infected adults with lipodystrophy. Tirzepatide's approval is broader: type 2 diabetes, chronic weight management in adults with obesity or overweight plus a weight-related condition, and moderate-to-severe obstructive sleep apnea. AOD-9604 has never been approved by the FDA or any other regulator for any indication; its obesity development program was discontinued after the pivotal human trial missed its endpoint, and any AOD-9604 sold today as 'research-grade' carries no approved quality, purity, or safety standard.
Key caution
Each compound's defining caveat differs. For AOD-9604, it's simply that the human efficacy case was never made — the mechanism is elegant, the animal data encouraging, but the people who actually took it in trials did not lose more weight than those on placebo [3]. For tesamorelin, the caution is that its clear, replicated benefit is not permanent — visceral fat returns once treatment stops, and its approval does not extend beyond the HIV-lipodystrophy population it was tested in [10]. For tirzepatide, the caution is the flip side of its potency: a well-documented, dose-related gastrointestinal side-effect burden and a confirmed gallbladder / biliary-disease signal, both proportional to just how much metabolic activity the drug induces [13]. Reading the three together, the pattern is one of trade-offs, not a clean hierarchy.